WIGZELL HANS LENNART RUDOLF sold 26.6% of their position (5K shares) of SAREPTA THERAPEUTICS, INC. on the open market
Open‑market sale worth $753.2K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 5/22/2020ACC: 0001209191-20-031881
Director
Since Nov 2018
-5K
Net shares
Net seller
$753.2K
Total sold
3
Open market trades
0B · 3S
5
Total transactions
5K acquired · 10K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
+5K
Price / share
$10.08
Trade value
$50.40K
% of position
36.3%
5/20/2020
13.79K→18.79K
Common Stock
Direct
Shares
−2.10K
Price / share
$149.62
Trade value
$314.20K
% of position
11.2%
5/20/2020
18.79K→16.69K
Common Stock
Direct
Shares
−2.05K
Price / share
$151.22
Trade value
$309.40K
% of position
12.3%
5/20/2020
16.69K→14.65K
Common Stock
Direct
Shares
−854.00
Price / share
$151.77
Trade value
$129.61K
% of position
5.8%
5/20/2020
14.65K→13.79K
Total
Net shares
+0.00
Net value
-$702.81K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 5/20/2020 | M · Option Exercise | +5K | $10.08 | $50.40K | 36.3% | 13.79K | 18.79K |
| Common Stock Direct | 5/20/2020 | S · Sale | −2.10K | $149.62 | $314.20K | 11.2% | 18.79K | 16.69K |
| Common Stock Direct | 5/20/2020 | S · Sale | −2.05K | $151.22 | $309.40K | 12.3% | 16.69K | 14.65K |
| Common Stock Direct | 5/20/2020 | S · Sale | −854.00 | $151.77 | $129.61K | 5.8% | 14.65K | 13.79K |
| Total | +0.00 | -$702.81K | ||||||
Derivative Transactions1
Stock Oprion (right to buy)
Direct
Converts to
Common Stock
5K shares
Shares
−5K
Strike price
10.08
Held after
0.00
Exercisable
—
5/20/2020
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Oprion (right to buy) Direct | Common Stock5K shares | 5/20/2020 | M · Option Exercise | −5K | 10.08 | — | 0.00 |